Three Research Peptides on the Radar. None of Them Approved.

The short version

peptideradar tracks compounds that are still in the pipeline — not on a pharmacy shelf. The three covered here are retatrutide, MOTS-c and KPV. None is an approved medicine in any jurisdiction, and the honest one-line summary of all three is that the evidence behind them is thinner than the enthusiasm around them.

They sit at very different stages, and that difference is the whole point of this site. Retatrutide has been through real trials in real people — Phase 1 and Phase 2 completed, Phase 3 still running — so there are measured numbers to quote ^[1][4]. MOTS-c has been studied mostly in mice and in cultured cells; its human data are observations of a naturally occurring peptide, not tests of an injected one ^[9][10]. KPV has no published human clinical trials at all: its entire efficacy record is laboratory work and mouse models of bowel inflammation ^[15][17].

A striking mouse result and a 48-week randomised trial are not the same kind of claim, even when both get called promising online. This desk keeps them apart.

What "research peptide" actually means

Peptides are short chains of amino acids — the same units that build proteins, only far smaller. Retatrutide is 39 amino acids long, MOTS-c is 16, and KPV is 3. Length matters, because short peptides are broken down quickly in the body, which is why so much of this literature is really about delivery: fatty-acid tails, transporters and nanoparticles that keep the molecule intact long enough to do anything at all.

The phrase research peptide is doing a lot of quiet work in the wider market, and it is worth unpacking. It covers two very different situations:

• Investigational drug. Retatrutide is a pharmaceutical candidate in company-run clinical trials. It has a sponsor, a trial protocol, a manufacturing standard and published results — but no approval from the FDA or any other regulator as of 2026, and no legal availability outside a trial ^[1].
• Research chemical. MOTS-c and KPV are sold by chemical suppliers for laboratory use only. There is no approved indication, no approved formulation, and no regulatory oversight of identity, purity or sterility. Their published record is preclinical.

Neither status means early version of a medicine. Both mean not established yet, and material bought through unregulated channels carries no verified guarantee that its contents match its label.

Why these three sit together on the radar

This hub is organised around the emerging research pipeline rather than around a single mechanism, which is why the three compounds here have almost nothing pharmacologically in common. What they share is a position: each is a compound generating far more attention than settled evidence, and each fails in a different way to meet the bar people assume it has cleared.

• Retatrutide is the near-term case. It engages three receptors at once — GLP-1, GIP and glucagon — and in a 48-week Phase 2 obesity trial the 12 mg group showed a mean body-weight change of -24.2% against -2.1% on placebo ^[4]. That is a large, well-documented effect from a randomised trial. It is also still Phase 2 data on an unapproved molecule, with long-term outcomes trials ongoing and unreported ^[1].
• MOTS-c is the mechanism-rich, evidence-poor case. It is encoded inside the mitochondrial genome, it activates AMPK, and it moves into the nucleus under metabolic stress ^[12]. Exogenous MOTS-c improved running capacity in aged mice ^[11]. No human interventional trial has tested whether any of that transfers.
• KPV is the earliest case of the three. It is the tail end of a human hormone, it suppresses inflammatory signalling at nanomolar concentrations in intestinal cells, and it reduces colitis severity in mice ^[15][16]. Human clinical evidence: none published.

Read together, they compare these peptides as a ladder of evidence maturity rather than a ladder of potency. The most-studied compound here is the one with the clearest documented harms, and the least-studied is the one with the cleanest-looking safety record — which is exactly what an absence of data looks like.

How to read the evidence on this site

Every claim on peptideradar carries a bracketed number pointing to a numbered source on the references page. Where a claim has no number, it is because no source in this digest supports it — and the page says so rather than filling the gap.

The tiers used throughout, strongest first:

1. Randomised controlled trials in humans. Participants assigned to compound or placebo, outcomes measured against a comparison group. On this site, only retatrutide has these ^[4][5][6].
2. Observational human data. Measurements of a naturally circulating peptide correlated with outcomes. Useful for generating hypotheses, incapable of proving that injecting the peptide does anything. MOTS-c's human record is this tier ^[9].
3. Animal studies. Mouse and rat work, where dose, timing and genetics are controlled in ways human life never is. Most MOTS-c and KPV efficacy data live here ^[11][13][16].
4. Cell and cell-free work. Mechanism at the molecular level, several removes from a whole organism ^[2][8][15].

A finding at tier 3 or 4 is not worthless — it is where every real drug begins. It is simply not evidence that a compound works in people, and the distance between the two is where most peptide marketing lives.